BFM
PCVX icon

Boothbay Fund Management’s Vaxcyte PCVX Stock Holding History

Boothbay Fund Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.7M Buy
+201,300
New +$10.9M 0.15% 111
2024
Q4 		– Sell
-3,600
Closed -$411K – 1817
2024
Q3 		$411K Buy
+3,600
New +$324K 0.01% 1070

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's PCVX Position: Q1 2026 in Review

Boothbay Fund Management increased its Vaxcyte (PCVX) stake by 4.9% in Q1 2026, buying an estimated $1.32M and bringing the position to 522,019 shares worth $30.3M. The position accounts for 0.39% of the portfolio, ranked #19.

Boothbay Fund Management first reported a position in PCVX in Q2 2020 and has held it in 17 quarters since. 336 funds tracked by Wall St. Rank hold PCVX as of Q1 2026.

  • Boothbay Fund Management held 522,019 shares of Vaxcyte worth $30.3M as of Q1 2026.
  • Boothbay Fund Management bought 24,279 Vaxcyte shares in Q1 2026, an estimated $1.32M.
  • Vaxcyte made up 0.39% of Boothbay Fund Management's portfolio in Q1 2026, its #19 holding.
  • Boothbay Fund Management first reported a position in Vaxcyte in Q2 2020 and has held it in 17 quarters since.
  • 336 funds tracked by Wall St. Rank held Vaxcyte as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.